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Abstract 
Regulatory approval of follow-on biologics and other generic versions of complex 
pharmaceutics requires that a potential biosimilar (test) product demonstrates similarity to an 
innovator (reference) product through a stepwise, totality of the evidence approach. Although the 
best statistical approaches for assessing analytical similarity are still under debate, these 
investigations rely heavily upon comparability of a given pharmaceutical’s critical quality 
attributes (CQAs) – physicochemical and biological properties that are most relevant to clinical 
safety and efficacy. Selection of proper CQAs from the large amounts of physical, chemical, and 
biological data needed for sufficient characterization of these kinds of pharmaceutics can be 
difficult due to their inherent complexity and heterogeneity. Crofelemer, a botanically sourced 
polymeric proanthocyanidin, exhibits significant variation in final drug product resulting from 
processing and purification of the raw material and the botanical nature of the crude source 
material. From a single lot of crofelemer, various physically and chemically degraded samples 
were produced in an effort to create artificial lots with varying “similarity” to the reference 
starting material. Physical, chemical, and biological variability of the original and artificial lots 
were investigated using a variety of spectroscopic, chromatographic, mass-spectrometry, and 
biological techniques. The entirety of the analytical data collected for each crofelemer lot was 
then utilized in a machine learning approach to identify individual and/or combinations of CQAs 
which can accurately identify and distinguish subtle variations between the complex drug 
product (crofelemer) and the artificial lots comprised of its adulterated forms.  
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1. Introduction 
Biological and polymeric pharmaceutics are inherently more physically and chemically 
complex than small molecules. The consistency of these complex pharmaceutics is highly 
dependent on factors such as manufacturing processes and source materials. Accurate and 
sufficient characterization of each batch is crucial for ensuring the quality and efficacy of these 
therapeutic agents. To streamline this characterization, critical quality attributes (CQAs) are 
identified during development, which provide the most pertinent information for ensuring batch 
consistency and clinical outcome. Critical quality attributes are product specific, and variations 
in these attributes must be identified and accurately distinguished from the inherent 
heterogeneity of these complex pharmaceutics. Selecting relevant CQAs remains a difficult, yet 
necessary, step in the development of biological and other complex pharmaceutics.  
Crofelemer is a botanically sourced polymeric proanthocyanidin currently approved by 
the FDA for the treatment of noninfectious secretory diarrhea in HIV/AIDs patients taking anti-
retroviral therapies. Crofelemer is isolated from the red latex sap of the South American tree 
Croton lechleri. Hence, there is the potential for significant drug product variation arising from 
processing and purification of the raw material and the botanical nature of the crude latex source, 
e.g. growth conditions and specimen biodiversity. Crofelemer is a random polymer of (+)-
catechin, (+)-gallocatechin, (-)-epicatechin, and (-)-epigallocatechin units. Polymer chains 
contain 1 to 28 repeating units and a number average of 5 to 7.5 units (Figure 1). 
In 2010, the FDA established an abbreviated licensure pathway for the approval of 
“highly similar” versions of currently approved biological drugs. While statistical methods for 
evaluating similarity are still under debate, these methods all attempt to evaluate analytical 
similarities between test and reference compound CQAs. Hence, a fast and reliable method of 
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identifying CQAs through interpretation of vast amounts of variable physical, chemical, and 
biological characterization data, across lots and within lots themselves, is a key step in 
demonstrating biosimilarity of complex pharmaceutics. 
In this study, 1H and quantitative 13C NMR techniques along with a kinetic fluorescence 
assay monitoring chloride ion efflux of T84 cell monolayers will be used to help characterize and 
evaluate a range of subtly degraded forms of single lot of crofelemer. This data was used in 
combination with a variety of other analytical methods through a machine learning approach to 

























R = H or OH
n = 1-28; average n = 3 to 5.5
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2. Background 
2.1 Biotherapeutic Complexity and Similarity Assessment  
The market for complex biotherapeutics has grown rapidly over the past few years into a 
multi-billion dollar industry, with 7 of the top 10 selling pharmaceuticals of 2014 being biologics 
(PMLiVE, 2016; Van Arnum, 2013). These impressive sales can most easily be contributed to their 
significantly larger costs compared to small molecule therapies, many in the order of several 
thousands of dollars per treatment. While extremely effective in their applications, the high price 
tags associated with treatment limit their practicality, and consequently their use, toward disease 
treatment. The inherent complexity of these molecules makes them difficult to produce, and 
often the consistency of a final product depends heavily on manufacturing process and source of 
origin. This heterogeneity must be well characterized, controlled, and documented when 
companies pursue regulatory approval. The time and expense associated with preliminary 
research, manufacturing, and regulatory approval translates into higher costs for patients taking 
theses types of drugs. Recently, various regulatory agencies (EMA, Japan, Canada, FDA) have 
established abbreviated regulatory guidelines for the approval of generic versions of these 
biological drugs, coined “biosimilars.” By providing sufficient evidence of “similarity” between 
a potential biosimilar (test) product and a currently approved biological (reference) product, the 
competitor may be allowed to forgo extensive clinical investigations usually necessary for 
approval of innovator products. As patents begin to expire on brand name biological drugs, the 
market will open up for other companies to sell their own generic versions. The reduced capital 
costs for biosimilar approval and market competition will hopefully reduce the high costs 
currently associated with brand name biological drugs, increasing their application. However, 
there is still a need for a reliable, high(er) throughput means for determining “similarity” 
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between brand name biotherapeutics and a respective reference compounds. Streamlining this 
similarity determination will result in reduced time and cost toward approval, making 
biotherapeutics a more viable treatment option for patients. 
 
2.2 Secretory Diarrhea and Chloride Ion Channels 
Diarrhea continues to be a substantial contributor of morbidity and mortality 
worldwide("Diarrhoeal disease," April 2013). Diarrhea itself has various etiologies, and in many cases 
secretory mechanisms play a substantial role in disease severity. Secretory diarrhea occurs 
primarily through over-activation of chloride ion channels expressed by the epithelial cells that 
comprise the intestinal mucosa. These chloride channels help to regulate Cl- ion concentrations 
in the intestinal lumen, which together with Na+ helps regulate the osmotic gradient across the 
gut wall. The most common and well-understood perpetrators of secretory diarrhea are strains of 
Vibrio cholerae and Escherichia coli bacteria(Yeo, Crutchley, Cottreau, Tucker, & Garey, 2013). V. cholerae and 
E. coli secrete toxins (cholera toxin and E. coli heat-liable and heat-stable toxins, respectively) 
which initiate a signal cascade resulting in higher intracellular concentrations of cyclic adenosine 
monophosphate (cAMP) and subsequently increased Protein Kinase A (PKA) activity. PKA then 
phosphorylates the cystic fibrosis transmembrane conductance regulator (CFTR), initiating 
secretion of intracellular Cl- ions out of the cell and ultimately leading to accumulation of water 
in the luminal space.  
There is growing evidence which suggests viral infections can initiate secretory and other 
forms of diarrhea(Lorrot & Vasseur, 2007). Rotavirus nonstructural protein (NSP4) is also classified as 
an enterotoxin, and has been shown to increase available intracellular concentrations of Ca2+ 
ions(Dong, Zeng, Ball, Estes, & Morris, 1997). Higher levels of intracellular Ca2+ can stimulate activation of 
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calcium activated chloride channels (CaCC), which are also responsible for Cl- ion efflux into 
the luminal space. The presence of transactivating factor protein (Tat), expressed during HIV-1 
infection and replication, has been attributed to increased Cl- ion secretion. This increased efflux 
was found to be mediated by intracellular Ca2+ concentration and not cAMP or cGMP 
dependent(Canani et al., 2003). Presence of the HIV envelope protein, glycoprotein gp120, has also 
been shown to result in α-tubulin depolymerization and loss of in vitro membrane stability(Maresca 
et al., 2003). 
When considering CFTR and CaCC, and the variety of ways in which they can be 
activated, it is not surprising that around 60% of patients diagnosed with HIV suffer from some 
form of HIV-associated diarrhea at some point during disease progression(Zingmond et al., 2003). In the 
past, opportunistic bacterial and/or viral infections evading destruction in the GI tract due to 
immune compromise could easily be attributed to acute and chronic diarrheal symptoms. 
Instances of opportunistic pathogenesis have decreased since the implementation of highly active 
antiretroviral therapy (HAART). However, several noninfectious etiologies have been identified 
which contribute to diarrheal symptoms. Idiopathic HIV enteropathy, autonomic neuropathy, and 
chronic pancreatitis are a few identified contributors to HIV-associated diarrhea. HAART-
associated diarrhea has also been identified, affiliated with HIV/AIDs therapeutics such as 
nucleoside and non-nucleoside reverse transcriptase inhibitors, integrase inhibitors, and 
specifically protease inhibitors, which list diarrhea as a common side effect(MacArthur & DuPont, 2012). 
In vitro and human studies suggest that commonly used protease inhibitors can induce Ca2+ 
chloride channel dependent secretory diarrhea, further contributing to HIV-associated 
diarrhea(Rufo et al., 2004). 
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2.3 HIV-Associated Diarrhea Treatments and Fulyzaq® 
Proper diagnosis of HIV-associated diarrhea is necessary to best prescribe effective 
treatment. In the case of pathogenic etiology, the specific pathogen(s) responsible should be 
identified and treated with appropriate antibiotics, antiparasitics, and/or antifungals. (Feasey, Healey, & 
Gordon, 2011). If the cause of diarrhea is non-pathogenic, such as HAART-associated diarrhea or 
HIV enteropathy, current treatment options are limited and only supportive in nature. Adsorbent 
treatments contain some form or combination of adsorbents such as attapulgite and/or bismuth 
subsalicylate, the active ingredients in Pepto-Bismol. Anti-motility agents are another widely 
used option. Drugs such as loperamide and diphenoxylate/atropine limit peristalsis of the 
intestine, increasing transit time allowing for increased fluid absorption. Lastly, antisecretory 
agents such as bismuth subsalicylate and most recently, crofelemer, have been used in alleviating 
HIV-associated diarrhea(MacArthur & DuPont, 2012). 
Fulyzaq® is an orally dosed, enteric-coated formulation containing 125 mg of dry 
crofelemer API along with various excipients. Fulyzaq® is currently sold by Salix 
Pharmaceuticals, Inc., and was approved by the FDA in late 2012 for the symptomatic treatment 
of secretory diarrhea in HIV/AIDS patients taking anti-retroviral therapies, and is one of four 
currently approved FDA approved polymeric APIs (sevelamer, heparin, glatiramer acetate). 
Crofelemer acts to inhibit CFTR and CaCC channels in the GI tract, preventing excess Cl- efflux 
into the luminal space. As a result, patients taking crofelemer saw a significant clinical response 
(17.6% taking crofelemer, 8.0% taking placebo, 1-tailed p<0.01). Crofelemer was shown to have 
very little ability to permeate the intestinal wall, and because of this its inhibition of Cl- channels 
is limited to the GI tract. 
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2.4 Introduction to Crofelemer 
 Crofelemer is a botanically sourced polymer refined from the stem bark latex of the 
Croton lechleri tree endogenous to South America. This red latex, commonly referred to as 
“Sangre de Drago” or “dragon’s blood” (Figure 2) is a widely used traditional medicine for the 
treatment of cough and flu, diarrhea, stomach ulcers, lacerations, sores, herpes infection, and 
wound healing(Ubillas et al., 1994). Efforts in the scientific community have been made to utilize these 
therapeutic properties through development of more refined versions of this latex. These 
fractions, most notably SP-303, were investigated for their anti-viral and anti-secretory 
properties through various application strategies. Eventually trademarked under the name 
crofelemer, SP-303 is a mixture of proanthocyanidin oligomers composed of (+)-catechin, (+)-
gallocatechin, (-)-epicatechin, and (-)-epigallocatechin subunits with an average degree of 
polymerization of 5 to 7.5 units, but with a range from 1-28 repeating units. Among the repeating 
catechin and gallocatechin units are believed to be trace amounts of anthocyanidin molecules, 
which give crofelemer its characteristic dark red color, though these minor units have yet to be 
identified. 
Investigations into crofelemer’s anti-secretory properties determined it acts preferentially 
to inhibit the CFTR and CaCC chloride channels. Patch clamp and Ussing chamber studies 
indicate Cl- channel inhibition in a concentration dependent manner(Fischer et al., 2004; Gabriel et al., 1999; 
Tradtrantip, Namkung, & Verkman, 2010). In one study, increasing concentrations of orally dosed, enteric-
coated crofelemer resulted in decreasing amounts of intestinal fluid accumulation in 8-10 week 
old C57B1/6 mice when challenged with cholera toxin administration(Gabriel et al., 1999). 
Investigations using CFTR inhibitors in combination with CaCC agonists (ATP or thapsigargin) 
indicate fast and almost total inhibition of CaCC Cl- ion efflux, whereas CFTR Cl- ion efflux in 
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the presence of the cAMP agonist forskolin only showed limited inhibition. Though washout of 
non-absorbable anti-secretory agents can occur in instances of diarrhea can be common, various 
concentrations of crofelemer were able to retain over 50% of their inhibitory effect toward CFTR 
challenge up to 4 hours. Co-inhibition studies with CFTR inhibitors thiazolidinone or glycine 
hydrazide showed non-competitive inhibition of Cl- ion efflux, suggesting different CFTR 
inhibition sites(Tradtrantip et al., 2010). The exact mechanism of action of crofelemer for CaCC and 
CFTR inhibition is unknown. 
 
 
Image Source: https://upload.wikimedia.org/wikipedia/commons/9/9c/Sangre_de_Grado.jpg 




2.5 Critical Quality Attributes, Mathematical Modeling, and Similarity 
Assessment 
As a botanically sourced polymer, substantial variability in finalized crofelemer drug 
product can occur based on harvesting location, environmental conditions, purification and 
manufacturing processes. Robust, reliable analysis of crofelemer composition batch to batch is 
necessary to ensure its safety and efficacy before distribution and sale. In every complex 
biological product, certain chemical and/or physical characteristics may be more indicative of 
changes in safety and/or biological activity than others. These information rich features, dubbed 
critical quality attributes (CQAs), should be identified and monitored for comparability 
assessment between different lots of complex drug product. CQAs are inherent to every drug 
product, and proof of similarity between CQAs of innovator drugs (reference products) and 
potential generic forms (test products) is necessary in determining comparability as outlined by 
the regulatory approval processes for generic complex biological drugs which are highly 
dependent on manufacturing process and source of origin. 
In recent years the FDA has outlined a stepwise approach toward obtaining biosimilarity 
or interchangeability status of a test compound. This stepwise approach focuses on acquiring a 
totality-of-the-evidence with which to establish proof of similarity to a reference product. This 
evidence starts with extensive analytical studies of both the test and reference material, in an 
effort to establish relevant CQAs with which to perform comparison. These CQAs are split into 
three tiers. The FDA recommends an equivalency test for tier 1 CQAs, which have been shown 
to have the most influence on clinical outcomes. An appropriate quality range should be 
established for CQAs which fall into tier 2 (moderate clinical impact), while graphical 
presentation/comparison is sufficient for tier 3 CQAs(Chow, Song, & Bai, 2016). While the best statistical 
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methods with which to perform comparisons in each tier is still under debate, reliable and robust 
identification of CQAs for each biosimilarity case is an important first step in establishing 
regulatory approval. 
By applying a machine learning approach using large amounts of physical, chemical, and 
biological characterization data, mathematical models that can identify information rich, product 
specific CQAs can be developed. Once a model has been established, it can then be applied for 
fast and reliable comparability assessment of generic forms against currently approved complex 
therapeutics, as well as batch-to-batch quality assurance. These models will assist companies 
developing follow-on biologics and other forms of complex pharmaceuticals to make informed 
decisions and identify relevant analytical assays for similarity assessment in a more cost and time 




 Fulyzaq® tablets (Silax Pharmaceuticals, Lot #s 3118488, 3117608, and 3128292) were 
acquired from local pharmacies (Sigler Pharmacy, WE Pharma). Deuterium oxide (D2O) was 
purchased from EMD Millipore Corporation (Billerica, MA, USA). Double distilled water 
(ddH2O) was used for buffer preparations, while ultrapure water was used for preparation of 
crofelemer samples for use in all bioassays. Amicon® Ultra-15 3 kDa and 10 kDa MWCO 
centrifuge filters were purchased from Merck Millipore Ltd. (Tullagreen, Carrigtwohill Co. Cork, 
Ireland). Wilmad 500 MHz thin wall NMR tubes were purchased from Milmad LabGlass 
(Vineland, NJ, USA). T84 cells (passage 55) were purchased from the American Tissue Culture 
Collection (ATCC, Manassas, VA, USA). DMEM:F12 media + L-Glutamine and 2.438 g/L 
sodium bicarbonate was purchased from Life Technologies (Grand Island, NY, USA). Fetal 
bovine serum (FBS) was purchased from Atlanta Biologicals (Atlanta, GA, USA). A 0.25% 
Trypsin, 2.21 mM EDTA solution was purchased from Mediatech, Inc. (Manassas, VA, USA). 
N-(Ethoxycarbonylmethyl)-6-Methoxyquinolinium Bromide (MQAE) was purchased from 
Biotium, Inc. (Hayward, CA, USA). Forskolin and Ionomycin were purchased fro LC 
Laboratories (Woburn, MA, USA). Quercetin was obtained from Sigma Aldrich (St. Louis, MO, 
USA). Ethanol, 190 Proof, was purchased from Decon Laboratories, Inc. (King of Prussia, PA, 
USA). Buffer salts used in chloride channel assays were obtained from Fisher Scientific (Fair 
Lawn, NJ, USA). Costar 3603, Black, clear bottom tissue culture treated 96 well plates and 75 




3.2.1 Fulyzaq® API Extraction 
 The enteric coating of Fulyzaq® tablets (consisting of ethylacrylate and methylacrylate 
copolymer dispersion, talc, triethyl citrate, and a white dispersion composed of xanthan gum, 
titanium dioxide, propyl paraben, and methyl paraben) was carefully removed using a clean 
razorblade. The packed pill containing a mixture of 125 mg of crofelemer dispersed in insoluble 
excipients (microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and 
magnesium stearate) was gently crushed into a powder. Crofelemer and excipients were then 
dissolved directly into 5 mL/pill of ultrapure H2O (or D2O for NMR samples) and vortexed to 
yield a 25 mg/ml solution of crofelemer. The dissolved drug and excipient suspension was 
centrifuged at 3,700 xg for 1 hour, and the supernatant was collected. Unfractionated samples 
were aliquoted and either tested immediately, frozen (-80ºC), or incubated at controlled 
temperatures for forced degradation studies. 
 
3.2.2 Crofelemer Fractionalization and Forced Degradation of Samples 
 Crofelemer was fractionated using 3-kDa and 10-kDa molecular weight cut-off (MWCO) 
centrifuge filters. A 10 mL solution (25 mg/ml) of unfractionated crofelemer was added to the 
top of the respective centrifugal filters and centrifuged at 4,000 xg for 30 minutes on an 
accuSpinTM 3R swing bucket centrifuge (Fisher Scientific, Fair Lawn, NJ). Concentrate was 
diluted with ddH2O (or D2O for NMR samples) back to 10 ml and centrifuged under the same 
conditions a second time. Concentrate was again diluted to 10 ml. Aliquots of concentrate, 
deemed “Top” and filtrate, deemed “Bottom” were then prepared alongside unfractionated 
samples. NMR samples (unfractionated and Top fractions) were stored at 25 mg/ml at their 
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respective temperatures (25ºC and 40ºC) in a controlled environment until time-points were 
reached, at which point spectra were either collected immediately or samples were frozen until 
readings could be taken. Top and unfractionated crofelemer samples for biological testing were 
first diluted to 0.5 to 0.4 mg/ml before preparing aliquots. Time zero samples were frozen 
immediately (-80ºC) while degradation samples were stored at their respective temperatures 
(25ºC and 40ºC) alongside NMR samples. Bioassays of degraded samples were tested as time-
points were reached, or samples were frozen until assays could be performed. Table 1 
summarizes the tested sample temperatures and time points. 
 
Table 1: Forced degradation sample temperatures and time-points tested. 
 
Unfractionated, 10 kDa Top, and 3 kDa Top Samples 
 25ºC 40ºC 
Time Zero 7 day 30 day 7 day 30 day 
T84 Assay      
1H NMR and 
Quantitative 
13C NMR 
 NT*  NT  
* NT: not tested 
 
3.2.3 1H and Quantitative 13C NMR of Forced Degradation Samples 
 1H NMR spectra of (+)-catechin, epigallocatechin gallate, and crofelemer samples were 
obtained using an Avance 400 MHz NMR (Bruker, MA) spectrometer. A total of 128 scans were 
collected per 1H NMR sample. Quantitative 13C NMR spectra of crofelemer samples were 
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collected using an Avance AVIII 500 MHz NMR spectrometer (Bruker, MA) equipped with a 
dual carbon/proton (CPDUL) cryoprobe, using a zgig pulse program, 3200 scans, with a 25 
second interscan delay. All samples were dissolved in D2O. One-month incubated samples (25°C 
and 40°C) showed visual evidence of precipitation and were centrifuged for 15 min at 14000 x g 
in a Sorval Legend Micro 17 Centrifuge (Thermo Scientific, US) to exclude particulates before 
spectra were recorded. Spectra were manually phase corrected and appropriately baseline 
corrected using MestRe Nova 9.0 (Mestrelab Research, S. L.) before data analysis. Previously 
reported 13C NMR shift values for crofelemer are shown in Figure 3(Ubillas et al., 1994). 
The internal/terminal unit ratio (IU / TU) of each sample was calculated through 
integration of the C-4 δ 36.35 and δ 38.24 ppm signals of internal units and the δ 28.67 signal of 
its terminal unit counterpart. The ratio of 2,3-trans and 2,3-cis species within samples was 
determined through integration and comparison of the C-2 δ 82.9 ppm signal characteristic of the 
catechin and gallocatechin (2,3-trans) moieties, and the C-2 δ 76.6 ppm signal characteristic of 
the epicatechin and epigallocatechin (2,3-cis) moieties. The procyanidin (PC) and prodelphinidin 
(PD) composition of crofelemer could be estimated due to slight variations in signal 
contributions to the δ 146.2 ppm and δ 131.4, 133.9 ppm signals attributed to the B ring of the 
repeating units. Both catechin and gallocatechin units have two carbons which contribute to the δ 
146.2 signal seen in the 13C-NMR spectra, however catechin units only possess one carbon 
which contributes signal at around δ 133.9 ppm, while gallocatechin units have both a carbon 
that contributes to the δ 133.9 signal as well as a carbon which has a δ 131.4 ppm shift. We 
utilized this difference in signal contribution, along with the ratio of ~146 and ~131-133 signal 
ranges to determine the different contributions of both PC and PD moieties within the total 
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crofelemer sample. When applied to the normalized function for PC and PD contributions, we 
could calculate the percent composition of PC and PD within a sample: 
𝑆𝑖𝑔𝑛𝑎𝑙!"#!!" = 2𝑃𝐶 + 2𝑃𝐷 = 1 𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑  
𝑃𝐷 = 0.5− 𝑃𝐶 




𝑃𝐶 + 2(0.5− 𝑃𝐶)
2𝑃𝐶 + 2(0.5− 𝑃𝐶) =
𝐴𝑈𝐶 𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑡𝑜 𝑆𝑖𝑔𝑛𝑎𝑙 𝑎𝑡 146𝑝𝑝𝑚
1 (𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑)  
PC = 1− A𝑈𝐶 𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑡𝑜 𝑆𝑖𝑔𝑛𝑎𝑙 𝑎𝑡 146𝑝𝑝𝑚 
 
 
Figure 3: 13C NMR shift values for the repeating units of crofelemer(Ubillas et al., 1994). Changes in C2 
and C3 signals indicating trans and cis forms are highlighted in blue. Varying contributions to the δ 








































































































































































3.2.4 T84 Chloride Channel Inhibition Assay  
 T84 chloride channel inhibition assays were performed using a method adapted from 
West and Molloy (West & Molloy, 1996). T84 cells were maintained using 1:1 DMEM/F12 culture 
media with L-Glutamine and 2.438 g/L sodium bicarbonate supplemented with 5% (v/v) FBS in 
a controlled 5% CO2 atmosphere at 37ºC. Cells were initially plated onto T-75 tissue culture 
flasks and passaged at least twice before use in fluorescence assays. Cells were seeded onto 96 
well plates at a density of 2x104 cells/well, and culture media was changed every two days until 
all wells reached confluence. A 10-mM solution of the Cl- quenched fluorescent probe MQAE 
dissolved in 100 µL culture media was administered to each cell monolayer for 10 hours prior to 
sample testing.  
After MQAE incubation, culture media was removed and replaced with a Cl- containing 
buffer solution (buffer 1) (65mM NaCl, 1.2mM K2HPO4, 0.3 mM KH2PO4, 0.5 mM CaSO4, 0.5 
mM MgSO4, 5mM HEPES, 5mM Dextrose, pH 7.4). Monolayers were washed twice for 10 
minutes with 150 µL/well fresh buffer 1 on a ZD-9556-A Orbital Shaker (Madell Technology 
Corp, CA) at 65 rpm to establish intracellular/extracellular equilibrium Cl- concentration. 
Monolayers were then exposed to freshly prepared solutions of either 100 µM quercetin in buffer 
1 (positive control), 0.1 mg/ml crofelemer in buffer 1, or buffer 1 alone (negative control) for 5 
minutes. After 5 minutes, buffer 1 solutions were removed and replaced with 0.1 mg/ml 
crofelemer samples, alone and in the presence of either 10µM forskolin or 10µM ionomycin to 
challenge crofelemer’s ability to inhibit Cl- efflux. Crofelemer samples, with or without forskolin 
or ionomycin, were dissolved in Cl- free buffer (buffer 2) (65mM NaNO3, 1.2mM K2HPO4, 0.3 
mM KH2PO4, 0.5 mM CaSO4, 0.5 mM MgSO4, 5mM HEPES, 5mM Dextrose, pH 7.4), along 
with respective positive and negative controls. Quercetin, forskolin and ionomycin were 
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insufficiently soluble in buffer solutions alone and were presolubilized in 26 µl of 95% ethanol. 
Fluorescence measurements were taken immediately in 25-second intervals for 25 min, λex = 360 
nm λem = 460 nm. Figure 4 summarizes the steps involved in the microplate assay. Changes in 
fluorescence were determined by subtracting the time-zero relative fluorescence units (RFU) 
from subsequent measurements (Ft-F0), and curves were normalized between quercetin and 
blank controls for sample comparison. Samples were tested on three separate 96 well plates, 
eight wells per sample group per plate, for a total of 24 wells per sample group. All assays were 
carried out at room temperature (22ºC). 
Forskolin and ionomycin were first tested on T84 monolayers to ensure their ability to 
initiate Cl- channel efflux of their respective ion channels, CFTR and CaCC. The concentration 
of crofelemer tested was based on previous patch clamp and Ussing chamber studies involving 
Cl- measurement(Gabriel et al., 1999; Tradtrantip et al., 2010). Concentrations of forskolin and ionomycin were 
based on those used previously for assessing Cl- ion efflux in T84 monolayers(Gabriel et al., 1999; West 
& Molloy, 1996). 
 




3.2.5 Initial Lot Variability Investigation 
Since crofelemer is not a synthetically manufactured compound but rather a harvested 
ethnobotanical drug, there is inherent variation between lots of released drug product. Triplicate 
1H NMR and qCNMR spectra were collected as reported earlier for three different lots; Lot 1 
(3118488), Lot 2 (3117608), and Lot 3 (3125951), to first confirm differences in observable 
characteristics. The 1H NMR of mixture samples were collected using an Avance AVIII 500 
MHz NMR spectrometer (Bruker, MA) equipped with a dual carbon/proton (CPDUL) cryoprobe, 
16 scans.  
 
3.2.6 Mixture Studies 
Once batch-to-batch variability was confirmed, unfractionated samples of individual lots 
were then mixed together to form six artificial lots whose compositions are listed in Table 2. By 
mixing these lots in various ways, artificial lots with subtle variations were produced with which 
to test and further refine the mathematical model and CQA selection process. 
 
Table 2: Compositions of mixtures produced from the three different crofelemer lots. Values 
represent % compositions of each mix. 
Sample Mix 1 Mix 2 Mix 3 Mix 4 Mix 5 Mix 6 
Lot 1 10 10 33.3 - - - 
Lot 2 90 - 33.3 50 10 90 




4.1 NMR Characterization 
4.1.1 Initial NMR Studies 
Initially, 1H NMR were collected for two compounds representative of crofelemer’s 
monomeric units, (+)-catechin (Figure 5) and epigallocatechin gallate (Figure 6). The (+)-
catechin sample possesses two sets of doublets (δ 2.514, 2.534 ppm and δ 2.555, 2.574 ppm) for 
the C4-β proton and two sets of doublets (δ 2.848, 2.861 ppm and δ 2.888, 2.902 ppm) for the 
C4-α proton. A sextet (δ 4.198, 4.211, 4.217, 4.230, 4.236, 4.250 ppm) is observed for the proton 
located on C3. Signal from the C2 proton was obfuscated by the H2O impurity of the solvent. 
The A8 and A6 protons both displayed doublets (δ 6.017, 6.023 ppm and δ 6.100, 6.105 ppm 
respectively). The B2’, B5’, and B6’ proton shifts fell on the range of δ 6.851 to 6.949 ppm. 
The epigallocatechin gallate sample possesses two sets of doublets (δ 2.863, 2.868 ppm 
and δ 2.907, 2.913 ppm) for the C4-α proton and two sets of doublets (δ 2.969, 2.980 ppm and δ 
3.012, 3.024 ppm) for the C4-β proton. A singlet is present at δ 5.013 ppm. What appears to be a 
quintet (δ 5.528, 5.532, 5.537, 5.542, 5.547 ppm) can most likely be attributed to the C3 proton. 
Signal contributions from the A6 and A8 protons can be seen from δ 6.094 to 6.127 ppm. A 
strong singlet is present at δ 6.547 due to contributions of the B2’ and B6’ protons. Another 
strong singlet can also be seen at δ 6.956 ppm from the 2” and 6” proton signals. The shift values 
correspond well with previously published shift values of (+)-catechin and epigallocatechin 






Figure 5: 1H NMR spectrum of (+)-catechin in D2O. Shift values correlate well with those published 
































Figure 6: 1H NMR spectrum of epigallocatechin gallate in D2O. Shift values correlate well with 
those published previously for epigallocatechin gallate in d6-acetone, shown with corresponding 













































4.1.2 1H and Quantitative 13C NMR of Forced Degradation Samples 
The NMR spectra of crofelemer is not publically available, however there are published 
peak assignments for the precursor to crofelemer, SP-303. Ubillas et. al. reported broad peaks 
from δ 2.2-3.0, 3.2-5.4, and 5.5-7.3 ppm in their 1H NMR spectra of SP-303. 13C NMR of SP-
303 also contained broad peaks at δ 28.7, 36.4, 38.2, 66.7, 72.6, 73.7, 76.6, 78.8, 82.9, 96.5, 97.6, 
107.4, 109.2, 115.5, 116.8, 120.0, 121.1, 131.4, 133.9, 146.2, 155.4, and 157.6.  Proton NMR 
spectra for the first available lot of crofelemer (Lot 3118488) show broad peaks in the ranges of 
δ 2.0-3.1, 3.1-5.5, and 5.5-7.3 ppm. Quantitative 13C spectra for crofelemer possess broad peaks 
at δ 28.67, 36.35, 38.24, 66.69, 72.43, 73.83, 76.57, 78.79, 82.90, 96.44, 97.91, 107.59, 109.13, 
155.53, 116.44, 117.19, 120.22, 121.20, 121.96, 131.18, 131.64, 132.55, 133.92, 144.45, 146.25, 
155.32, and 157.55 ppm.  
1H NMR spectra for day 0 unfractionated, 10 kDa top, and 3 kDa top samples (Lot 
CF3117608) showed no change in peak positions (Figure 7). Sharp peaks (δ 3.5 to 3.8 ppm) 
present in the 10 kDa and 3 kDa MWCO filtered samples are characteristic of cellulose that 
contaminated the sample during centrifugal filtration. The day 30 unfractionated samples 
incubated at 25°C and 40°C displayed a broadening of any distinguishable characteristics present 
in the peaks of day 0 samples, with a significant decrease in overall signal intensity in the 40°C 




Figure 7: 1H-NMR Comparison of unfractionated, 10 kDa top, and 3 kDa top crofelemer samples. 
No substantial differences were observed across the unfractionated and top fraction crofelemer 
samples. The presence of sharp peaks (δ 3.5 to 3.8 ppm) in the 10 kDa top and 3 kDa top fractions 
are characteristic of cellulose contamination from the centrifugal filters(Isogai, 1997). 
 
 
Figure 8: 1H-NMR comparison of day 0 and 25°C, 40°C day 30 crofelemer samples. Smoothing of 
characteristic features and decrease in signal magnitude occurred during the 30 day degradation 
period.  
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For qCNMR analysis of the crofelemer samples, the overall positioning of peaks in the 
13C-NMR did not change throughout sample degradation. However, changes in peak intensities, 
as well as broadening of peaks resulted in detectable changes in peak integration and ratio 
determinations, which are indicative of chemical changes occurring within the sample entirety 
over time (Figure 9).  
 
 
Figure 9: Quantitative 13C-NMR comparison of day 0 and 25°C, 40°C day 30 crofelemer samples. 
Precipitation of sample over the 30 day period contributed to signal loss in the 40°C samples, 
making some sample IU/TU ratios unreliable. Residual acetone from the NMR tube was present in 
the unfractionated day 0 sample, as well as the 10 kDa top and 3 kDa top day 30 25°C degree 
samples. The signal contribution of the δ 31.2 ppm contaminant peak has been excluded in analysis 
of proximal peaks. 
 
Peaks of interest for determining IU/TU, Trans/Cis, and PC% and PD% were integrated and 










Table 3: Differences in IU/TU, Trans/Cis, and PC/PD Ratios for Crofelemer Samples as 
Determined by qCNMR. 
Sample Trans/Cis PC% PD% IU/TU 
Unfractionated, T0 0.69 31.16 68.84 6.76 
Unfractionated, 30 Day 
25°C 
0.82 34.51 65.49 4.93 
Unfractionated, 30 Day 
40°C 
IS* 50.54 49.46 IS* 
10kDa Top, T0 0.72 33.52 66.48 4.27 
10kDa Top, 30 Day 
25°C 
0.72 24.88 75.12 4.87 
10kDa Top, 30 Day 
40°C 
0.64 72.58 27.42 4.53 
3kDa Top, T0 0.58 23.60 76.40 3.79 
3kDa Top, 30 Day 25°C 0.73 47.33 52.67 3.61 
3kDa Top, 30 Day 40°C 0.77 43.02 56.98 4.27 
* IS: insufficient signal 
Day 0 unfractionated crofelemer had an IU/TU ratio of 6.76, resulting in an estimated 
number average molecular weight of 2,328 g/mol. An unexpected decrease in molecular weight 
was seen in the top fractions of both 10 kDa and 3 kDa MWCO centrifuge filters used, with 
estimated average molecular weights of 1,581 g/mol and 1,437 g/mol, respectively. A decrease 
in the IU/TU ratio was observed in the unfractionated sample after 30 days of incubation at 25°C 
relative to its corresponding day 0 counterpart due to an increase in terminal unit signal relative 
to total signal spectra, suggesting formation of terminal units through degradation of higher 
molecular weight species. Accurate integration of the δ 36.4, 38.2 ppm and 28.7 ppm peaks in 
the 30 day, 40°C unfractionated crofelemer sample was not possible, most likely due to sample 
loss by precipitation and more extensive physical and/or chemical degradations. Both 3 kDa and 
10 kDa top fractions showed slight increases in the IU/TU ratio for their 40°C, 30 day 
counterparts when compared to time zero values. 
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The trans/cis ratio increased from time zero values in the unfractionated and 3 kDa top 
fraction samples when compared to 30 day time points. These samples show a slight increase in 
the epicatechin and epigallocatechin population, reflected by a relative increase in the δ 76.6 
ppm signal when normalized to total signal of the spectrum. However 10 kDa top fractions 
showed very little change in trans/cis ratio, with relatively consistent signal contributions from 
both δ 76.6 and 82.9 ppm. 
The PC and PD percentages showed consistent trends across all three samples. Increases 
in PC% can be seen in unfractionated, 3 kDa and 10 kDa top fractions due to slight increases in δ 
146.2 ppm relative signal contribution along with decreased contributions from the δ 131-133 
ppm range. Excluding the 30 day 10 kDa top 25°C sample, every 30 day sample showed 
decreased relative signal from δ 131.4 and 133.9 ppm peaks, indicative of loss of the B-5’ 
hydroxyl of gallocatechin repeating units.  
 
4.2 T84 Chloride Channel Inhibition Assay 
 Forskolin and ionomycin, at concentrations of 10 µM in buffer 2, were sufficient to 
induce marked efflux of Cl- ion from T84 monolayers when compared to buffer 2 alone (Figure 
10). Forskolin produced a more rapid net efflux with a faster initial rate when compared to 
ionomycin and blank control. Surprisingly, ionomycin showed a slower initial rate of efflux 
when compared to blank control, however after 9.5 minutes fluorescence values exceeded those 
of the buffer alone, and continued to increase for the remainder of the experiment. 
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Figure 10: Initiation of Cl- ion efflux by 10 µM forskolin and ionomycin compared to buffer absent 
of any Cl- channel agonists. 
 
All samples of crofelemer tested were able to inhibit Cl- ion efflux from T84 cells, 
regardless of fractionalization, time, and temperature. Though there was visual evidence of 
variability between crofelemer time zero samples and their 7 and 30 day degraded forms, Cl- 
efflux levels persisted below passive Cl- efflux in every case. Fluorescence values for crofelemer 
samples when challenged by either ionomycin or forskolin also remained below blank control in 
all cases. Challenge with forskolin showed visibly higher Cl- efflux compared to crofelemer 
challenged by ionomycin and crofelemer alone, showing similar behavior to initial tests with 
initiators alone. Overall chloride efflux behavior when cells were stimulated with ionomycin 
varied across samples; however, fluorescent values remained at or slightly above Ft-F0 values 
for crofelemer alone. Fluorescence values for crofelemer were consistently above values seen for 
quercetin after 25 minutes, indicating that saturation of Cl- channels did not occur (Figure 11, 
Figure 12, Figure 13). 
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Fractionalization of crofelemer using 10 kDa and 3 kDa MWCO centrifuge filters had no 
noticeable effect on crofelemer’s ability to inhibit Cl- ion efflux, alone or when challenged with 






























































































































































































































































































































































































































































































































































4.3 Initial Lot Variability Investigation 
 Three separate batches of unfractionated crofelemer were acquired and analyzed in an 
effort to distinguish variability between different lots. Initial qCNMR studies confirmed variation 
in IU/TU ratios, trans/cis ratios, and PC and PD composition across the three lots tested; Lot 
#311848 labeled “Lot 1” (Figure 15, Table 4), Lot #3117608 labeled “Lot 2” (Figure 16, Table 
5), and Lot # 3125951 labeled “Lot 3” (Figure 17, Table 6). Lot 1 possessed the highest trans/cis 
ratio (1.209) amongst the three lots tested, with a comparable IU/TU (3.88) to that of Lot 2. Lot 3 
showed the highest IU/TU ratio (5.45) of the lots, with a comparable trans/cis ratio (0.672) to 
that of Lot 2. The PC and PD compositions across the three lots were similar, with a majority of 
prodelphinidin moieties. Differences in PC and PD compositions, IU/TU, and trans/cis ratios 




Figure 15: Triplicate spectra of Lot 1 (3118488). A) 1H NMR spectra. B) Overlaid qCNMR spectra. 
	






Figure 16: Triplicate spectra of Lot 2 (3117608). A) 1H NMR spectra. B) Overlaid qCNMR spectra.  
	






Figure 17: Triplicate spectra of Lot 3 (3125951). A) 1H NMR spectra. B) Overlaid qCNMR spectra. 
	
Table 6: Calculated values of interest for Lot 3 (3125951) replicates. 
 
 





Trans/Cis	 PC%	 PD%	 IU/TU	
Lot	1	 1.209	±	0.037	 26.0	±	5.8	 74.0	±	5.8	 3.88	±	0.14	
Lot	2	 0.725	±	0.057	 34.6	±	12.2	 65.4	±	12.2	 3.77	±	0.59	
Lot	3	 0.672	±	0.068	 34.9	±	3.3	 65.1	±	3.3	 5.45	±	0.52	
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4.4 Mixture Studies 
 Though data collection of the mixtures is still underway, subtle differences can be seen 
between the different mixtures. Newly tested samples of the isolated lots correlate well with 
those recorded previously for batch-to-batch variability assessment. Values for spectra collected 
so far (n=2 of 3) are summarized in Table 8. 
 
Table 8: Summary of calculated values from qCNMR for isolated lots and mixtures of 
unfractionated crofelemer. 
   
Trans/Cis	 PC%	 PD%	 IU/TU	
Lot	1	(n=2)	 1.235	±	0.079	 25.4	±	3.5	 74.6	±	3.5	 5.55	±	0.27	
Lot	2	(n=2)	 0.740	±	0.063	 38.8	±	1.1	 61.2	±	1.1	 3.26	±	0.22	
Lot	3	(n=2)	 0.678	±	0.003	 36.1	±	1.3	 63.9	±	1.3	 4.29	±	0.44	
Mix	1	(n=2)	 0.813	±	0.007	 40.8	±	3.8	 59.2	±	1.3	 4.23	±	0.07	
Mix	2	(n=2)	 0.696	±	0.040	 29.3	±	1.2	 70.7	±	1.2	 4.29	±	0.31	
Mix	3	(n=2)	 0.987	±	0.008	 27.4	±	3.3	 72.6	±	3.3	 5.81	±	0.22	
Mix	4	(n=2)	 0.723	±	0.016	 38.3	±	3.9	 61.7	±	3.9	 4.80	±	0.44	
Mix	5	(n=2)	 0.694	±	0.008	 24.5	±	3.8	 75.5	±	3.8	 4.19	±	0.30	
Mix	6	(n=2)	 0.693	±	0.009	 31.2	±	5.8	 68.8	±	5.8	 4.43	±	0.14	
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5. Discussion 
5.1 1H and Quantitative 13C NMR of Forced Degradation Samples 
Due to crofelemer’s heterogeneity and polymeric nature, the peaks in the 1H NMR 
spectra are considerably broad. The 2.0-3.1 ppm peak arises from the proton(s) located on the C4 
sp3 hybridized carbon. The 3.1-5.5 ppm peak consists of the signals from the C2 and C3 sp3 
hybridized carbons in their cis and trans conformations. The 5.5-7.3 ppm peak, perhaps the most 
distinctive peak in the 1H NMR spectra, is composed of a collection of protons off of the sp2 
hybridized carbons of the A and B rings of the repeating units. Broadening of any signature 
characteristics of the 1H NMR peaks occurred over the course of sample incubation. It is hard to 
say whether the decrease in signal intensity results from simple concentration decreases due to 
precipitation of sample over time, a result of Hydrogen-Deuterium exchange, or representative of 
actual chemical degradations/changes occurring within the sample. That being said, significant 
changes in the 5.5-7.3 peak in particular could be indicative of further oxidation and/or PD to PC 
conversions that may be occurring over time. 
The qCNMR spectra reveal more pertinent information about potential chemical and 
physical degradations that may occur in crofelemer over time. While some peak broadening did 
occur over the course of sample degradation, IU/TU, trans/cis ratios, and PC and PD percentages 
could be determined in most samples except for the 40ºC, 30 day unfractionated sample. When 
comparing time zero samples of unfractionated crofelemer to its MWCO fractions, a counter 
intuitive decrease in IU/TU ratios was observed. This could be contributed to retention of higher 
molecular weight fractions of crofelemer due to extensive hydrogen bonding with the polyphenol 
nature of the regenerated cellulose membrane used during sample preparations. Increases in the 
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IU/TU values of the 30 day, 40ºC fractionated samples compared to their time zero counterparts 
indicate potential chemical additions at the C4 position of terminal units. 
The trans/cis ratios of each fraction and their respective degraded forms did not reveal 
any consistent trends. It is possible that the presence of regenerated cellulose altered signal 
contribution to the δ 76.6 ppm peak for cis moieties, however no consistent increase in cis 
composition was seen between unfractionated and MWCO fractions(Idström et al., 2016). 
Increases in the presence of the procyanidin moieties, with consequent decreases in 
prodelphinidin moieties were observed across all fractions (excluding the 10 kDa Top, 30 day, 
25ºC sample). The decrease in the 131-133 ppm signal range relative to total signal of the spectra 
indicates a loss of the triphenol structure of the gallocatechin units at the C5’, C4’ and C3’ 
carbons. Interestingly an increase in the 146.2 ppm signal relative to total signal was observed. A 
simple conversion from gallocatechin to catechin units via loss of the C5’ hydroxyl should not 
result in an increase of 146.2 signal, as catechin and gallocatechin moieties contribute equally to 
this peak. 
 
5.2 T84 Chloride Channel Inhibition Assay 
 A fluorescent microplate assay was utilized for assessing total chloride efflux from T84 
monolayers to assess variations of activity between crofelemer and its adulterated forms. Ideally, 
degradation of the starting material should result in observable changes in a drugs ability to 
initiate a measurable response. Though the exact mechanism of crofelemer in the GI tract is not 
known, it has been shown to selectively inhibit CaCC and CFTR chloride channels(Tradtrantip et al., 
2010). T84 cells express both CaCC and CFTR channels. By comparing total passive Cl- efflux 
(Blank) to efflux measured in the presence of crofelemer samples, the overall ability of 
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crofelemer to inhibit Cl- efflux could be quantified. Challenge of the crofelemer samples was 
performed using selective initiators of either CaCC (ionomycin) or CFTR (forskolin) in an effort 
to distinguish potential loss of inhibitive activity toward single channels after crofelemer 
degradation had occurred. Quercetin, a highly similar monomeric form of the catechin and 
gallocatechin subunits which comprise crofelemer, was used at higher concentrations (100 µM) 
in an effort to saturate Cl- channels as a positive control. The subtle changes from the initial lot 
of crofelemer during the degradation process did not have any substantial effect on its ability to 
inhibit Cl- efflux. Degradation of crofelemer did not substantially impact the polymers ability to 
inhibit individual channels when challenged with forskolin or ionomycin. It is entirely possible 
that the extent of degradation investigated in this study was not substantial for creating detectable 
changes in the chloride channel assay. As a heterogeneous polymeric species, slight or even 
substantial degradation in the repeating units of the overall chains that comprise the polymer may 
not cause observable changes in activity with the assay used. If only a single repeating unit and 
not a coherent chain of catechin and/or gallocatechin of crofelemer is necessary for chloride 
channel inhibition, then minor degradations in a sample of crofelemer – though observable 
through analytical analysis – may not translate into distinguishable changes in biological 
activities. This assumption could be further supported by quercetin’s ability to inhibit chloride 
efflux as a single repeating unit mimic. 
 
5.3 Initial Lot Variability Investigation and Mixture Studies 
 Quantitative 13C NMR proved to be a data rich analytical tool when characterizing forced 
degradation samples of crofelemer. Unfortunately, due to limited sample availability and budget 
considerations, these degraded samples and their time zero counterparts were not tested in 
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triplicate. Because of this, the spectra could not be applied to initial model development using 
the machine learning approach. Regenerated cellulose contamination from the centrifugal filters 
used in the fractionation process also complicated top fraction analysis.  
In initial lot variability measurements and in the mixture study, 1H NMR and qCNMR 
spectra are being collected in triplicate to afford more statistical power to the data set. These 
spectra of the unfractionated lots and corresponding mixtures will be utilized in the mathematical 
modeling approach. While data collection of the final replicates is still underway, noticeable 




 In this study, 1H NMR and quantitative 13C NMR was used to characterize various lots, 
degradants, and mixtures of crofelemer. A fluorescence microplate assay using T84 cell 
monolayers was also used to assess the inhibitive activity of unfractionated, fractionated, and 
degraded forms of a single lot of crofelemer on two chloride ion channels, CaCC and CFTR. 
Quantitative NMR proved to be a powerful analytical tool for observing changes in a crofelemer 
sample’s average monomeric unit stereochemistry (trans/cis), number average molecular weight 
(IU/TU) and monomer compositions (PC and PD percentages). The T84 bioassay was unable to 
identify any significant differences between subtly degraded forms of crofelemer. Whether this is 
due to lack of sensitivity of the assay, lack of significant degradation to impact crofelemer 
activity, or degradations not specific or substantial enough to the structure(s) necessary for 
crofelemer activity is yet to be determined. After initial studies were performed on a single lot, 
the approach to NMR characterization was slightly modified to afford more statistical power and 
allow integration into mathematical model development and future crofelemer sample similarity 
assessment.   
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7. Future Work 
 The ultimate goal for the analysis of crofelemer and its degraded forms and mixtures is to 
combine this characterization data with other analytical techniques (UV-Vis, CD, FTIR, SEC, 
HILIC, RP-HPLC, and mass spectrometry). The entirety of the data set will then be used in a 
machine learning approach to develop a mathematical model capable of identifying assays or 
points of interest within assays (CQAs), which are most relevant to biological and clinical 
outcomes. The scope of this work will not encompass clinical data. Therefore correlation of 
CQAs identified by the models will be based on their ability to distinguish between subtle 
differences in samples tested. Improvements to the T84 bioassay are necessary to relate 
analytically observable differences in crofelemer samples to their ability to inhibit CaCC and 
CFTR. This optimization is currently underway, testing various concentrations of crofelemer 
tested and culture conditions used to reduce variability and improve sensitivity within the assay.  
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